January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Viking is developing VK2735 for metabolic disorders/obesity, VK2809 for NASH, and VK0214 for X-ALD